Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
34.88 USD | -1.91% | +14.89% | +18.19% |
12:26pm | North American Morning Briefing : Tech Still in -2- | DJ |
Apr. 25 | Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45 | MT |
Evolution of the average Target Price on Tandem Diabetes Care, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Tandem Diabetes Care, Inc.
Leerink Partners | |
Stifel Nicolaus | |
Citigroup | |
UBS | |
TD Cowen | |
BofA Securities | |
Jefferies & Co. | |
Baird | |
Barclays | |
Craig-Hallum | |
Wells Fargo Securities | |
Raymond James | |
Cowen | |
Piper Sandler | |
Wolfe Research | |
Lake Street | |
Oppenheimer | |
SVB Leerink | |
Berenberg Bank |
EPS Revisions
- Stock Market
- Equities
- TNDM Stock
- Consensus Tandem Diabetes Care, Inc.